Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Mirabile

Obstetrics & Gynecology Overland Park, KS Medical Doctor

NPI 1588608855 CMS profile 344193

4550 W 109Th St, Suite 130, Overland Park, KS 66211

Open in the dashboard

General payments

$8,601

559 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Mirabile of Overland Park, KS is reported in the CMS Open Payments database as having received $8,601 across 559 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $491 26
2024 General $733 58
2023 General $1,502 99
2022 General $1,925 134
2021 General $2,156 131
2020 General $999 61
2019 General $793 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Mirabile
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to James Mirabile were reported at $491. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year James Mirabile Obstetrics & Gynecology median Middle half National median
2019 $793 $172 $62–$391 $163
2020 $999 $94 $36–$222 $114
2021 $2,156 $136 $42–$369 $132
2022 $1,925 $160 $50–$433 $149
2023 $1,502 $169 $56–$423 $160
2024 $733 $152 $50–$371 $164
2025 $491 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,141 203 payments
  2. Pfizer Inc. $1,030 81 payments
  3. Galderma Laboratories, L.P. $630 31 payments
  4. Avion Pharmaceuticals $525 36 payments
  5. Mayne Pharma Inc. $437 33 payments
  6. Allergan Inc. $316 21 payments
  7. Sumitomo Pharma America, Inc. $299 18 payments
  8. Eisai Inc. $227 13 payments
  9. Astellas Pharma US Inc $225 14 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $220 15 payments
  11. Other $1,551 94 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,479 545 payments
  2. Education $122 14 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $937 68 payments
  2. LO LOESTRIN FE $859 44 payments
  3. PREMARIN $706 54 payments
  4. NURTEC ODT $623 49 payments
  5. ORILISSA $534 24 payments
  6. ORIAHNN $520 23 payments
  7. MYFEMBREE $423 30 payments
  8. ESTRING $384 29 payments
  9. QULIPTA $382 25 payments
  10. BOTOX $373 30 payments
  11. Other $5,680 360 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,184

Median for Obstetrics & Gynecology: 65

Drug cost

$27,841

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

35.2%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Imvexxy Estradiol Brand 25 $6,186
Progesterone Progesterone, Micronized Brand 163 $5,092
Estradiol Generic 118 $3,863
Levothyroxine Sodium Generic 191 $1,525
Armour Thyroid Thyroid,pork Brand 18 $1,413
Spironolactone Generic 126 $1,249
Synthroid Levothyroxine Sodium Brand 21 $1,214
Butalbital-Acetaminophen Butalbital/Acetaminophen Brand 11 $1,090
Estradiol (Twice Weekly) Estradiol Brand 23 $1,051
Bupropion Xl Bupropion Hcl Brand 45 $1,017

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $102
$102 — —
ZAVZPRET
  • PFIZER INC. $82
$82 — —
QULIPTA
  • AbbVie, Inc. $82
$82 — —
UBRELVY
  • AbbVie, Inc. $73
$73 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

559 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record